WWOX suppresses prostate cancer cell progression through cyclin D1-mediated cell cycle arrest in the G1 phase

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• WW domain-containing oxidoreductase (WWOX) is a known tumor suppressor in various cancers.
• WWOX's role in prostate cancer suppression, including its apoptotic mechanisms, is under investigation.

Purpose of the Study:

• To investigate the role and mechanism of WWOX in prostate cancer progression.
• To determine the impact of WWOX expression levels on prostate cancer cell behavior.

Main Methods:

• Analysis of WWOX expression in prostate cancer tissues and cell lines.
• In vitro and in vivo studies involving ectopic WWOX expression.
• Flow cytometry, immunoblotting, and GFP fluorescence assays to assess cell cycle progression.
• Analysis of cyclin D1 and apoptosis-related gene expression.
• Investigation of WWOX's effect on c-Jun-mediated cyclin D1 promoter activity.

Main Results:

• WWOX expression is significantly down-regulated in prostate cancer specimens and cell lines.
• Ectopic WWOX expression inhibits prostate cancer progression in vitro and in vivo.
• WWOX overexpression causes G1 phase cell cycle arrest without affecting sub-G1 phase.
• WWOX down-regulates cyclin D1 expression, a key driver of tumor progression.
• Restoration of cyclin D1 abrogates WWOX-mediated tumor suppression.
• WWOX inhibits c-Jun-mediated cyclin D1 promoter activity.

Conclusions:

• WWOX suppresses prostate cancer progression by inhibiting cell cycle progression at the G1 phase.
• The primary mechanism involves the negative regulation of cyclin D1 expression.
• These findings reveal a novel tumor suppressive pathway for WWOX in prostate cancer.